Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Volitinib in MET exon 14 mutated pulmonary sarcomatoid carcinoma and other NSCLC
CTR20160581Phase 2Completed
- Sponsor
- HUTCHMED
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of savolitinib in non-small cell lung cancer (NSCLC), lung sarcomatoid carcinoma (PSC), sponsored by HUTCHMED. Started Aug 2016; status: completed.
02
Drugs
savolitinib
03
Conditions
non-small cell lung cancer (NSCLC)lung sarcomatoid carcinoma (PSC)
Beyond the preview
Go deeper on CTR20160581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160581.